Analysts expect that Akari Therapeutics PLC (NASDAQ:AKTX) will report earnings of ($1.00) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Akari Therapeutics PLC’s earnings. Akari Therapeutics PLC posted earnings of $0.03 per share in the same quarter last year, which indicates a negative year over year growth rate of 3,433.3%. The firm is expected to announce its next earnings report on Thursday, November 9th.

On average, analysts expect that Akari Therapeutics PLC will report full year earnings of ($3.28) per share for the current financial year, with EPS estimates ranging from ($5.00) to ($1.55). For the next year, analysts expect that the company will post earnings of ($4.00) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Akari Therapeutics PLC.

Several analysts have issued reports on the stock. Chardan Capital reaffirmed a “neutral” rating and set a $2.50 price target (down from $6.00) on shares of Akari Therapeutics PLC in a research report on Friday, August 11th. Zacks Investment Research lowered shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price target on shares of Akari Therapeutics PLC in a research report on Friday, September 22nd. William Blair reaffirmed an “outperform” rating on shares of Akari Therapeutics PLC in a research report on Tuesday, July 4th. Finally, ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Akari Therapeutics PLC has an average rating of “Hold” and an average target price of $8.00.

Shares of Akari Therapeutics PLC (NASDAQ AKTX) traded down 5.95% on Thursday, hitting $6.96. 310,938 shares of the stock traded hands. The firm’s market capitalization is $81.96 million. The firm’s 50 day moving average is $5.40 and its 200 day moving average is $7.23. Akari Therapeutics PLC has a 52 week low of $3.18 and a 52 week high of $22.20.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/12/brokerages-expect-akari-therapeutics-plc-aktx-will-post-earnings-of-1-00-per-share.html.

An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent reporting period. 26.85% of the stock is owned by hedge funds and other institutional investors.

About Akari Therapeutics PLC

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics PLC (AKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.